JAN 23, 2017 12:28 PM PST

New Liver Cancer Drug Passes Phase 3 Trial

WRITTEN BY: Xuan Pham

Results from an international Phase 3 clinical trial offer renewed hope for thousands of people with liver cancer. Published in the journal The Lancet, researchers report that the drug regorafenib improved patient survival to over 11 months as compared to placebo.

Image: Medscape

The American Cancer Society estimates that nearly 40,000 new cases of liver cancer, also known as hepatocellular carcinoma, were diagnosed in the US in 2016. Of these, around 69% will die. Of note, most cases of primary liver cancer are associated with hepatitis B or C viral infection, while a smaller percentage is caused by excessive alcohol consumption.

One drug that’s proven effective for liver cancer is sorafenib. However, in cases where the cancer becomes resistant to sorafenib, doctors have little other options. As such, finding a new treatment for liver cancer is a huge imperative.

In particular, researchers at Bayer honed in on regorafenib, a multi-kinase inhibitor. This drug targets the receptor tyrosine kinase, and causes anti-angiogenic activities. It was approved by the FDA in 2012 for the treatment of metastatic colorectal cancer. The FDA also expanded the use of this drug for the treatment of inoperable gastrointestinal stromal tumors.

Following the success of regorafenib in these other cancer types, Bayer scientists tested the drug in liver cancer with similar success. Recently, a large international clinical trial that spanned152 sites in 21 countries offered more support for this drug in liver cancer.

The study included 573 patients with advanced liver cancer who were previously treated with sorafenib. In patients treated with regorafenib, researchers found that overall survival was 10.6 months versus 7.8 months with the placebo treatment. In addition, 2 participants showed almost complete remission.

"This study represents a breakthrough in the management of hepatocellular carcinoma, since it provides evidence for clinical benefits in an area that was an unmet medical need," said Josep Llovet, founder and Director of the Liver Cancer Program and Professor at the Icahn School of Medicine at Mount Sinai. "Regorafenib has shown it can improve survival in patients with advanced hepatocellular carcinoma progressing on sorafenib. Previously, no treatment was available for these patients.”

Of note, the team reported side effects with the treatment, the most common being hypertension, hand-foot skin reaction, fatigue, and diarrhea. In addition there were 88 deaths total from both the treatment and placebo group.

The team is pursuing future experiments that combine regorafenib with other available drugs.

Additional sources: The Mount Sinai Hospital

 

 

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
AUG 19, 2020
Cancer
Testing the Toxicity of CDK Inhibitors and Radiotherapy
AUG 19, 2020
Testing the Toxicity of CDK Inhibitors and Radiotherapy
Drug targets often focus on one thing, inhibiting or activating some critical function in a cell. Cancer drugs are no di ...
AUG 19, 2020
Immunology
Cancer Mutation Improves Chemo Drug Performance
AUG 19, 2020
Cancer Mutation Improves Chemo Drug Performance
When it comes to cancer biomarkers, it’s often the genetic signatures that are associated with poor patient outcom ...
AUG 26, 2020
Cancer
NAP-6: A Potential Candidate for the Treatment of Breast Cancer
AUG 26, 2020
NAP-6: A Potential Candidate for the Treatment of Breast Cancer
The body is an amazing and complex system of pathways, all working together in harmony. However, cancer can quickly disr ...
SEP 11, 2020
Cancer
Taking cancer treatment from a whole new angle
SEP 11, 2020
Taking cancer treatment from a whole new angle
New cancer research is looking at treatment for the disease from an entirely new angle: structurally. While chemotherapy ...
SEP 21, 2020
Cancer
The Protein ETV1 May Act as a Biomarker for Gastrointestinal Cancer
SEP 21, 2020
The Protein ETV1 May Act as a Biomarker for Gastrointestinal Cancer
Cancer is an incredibly diverse disease. It has many types and even sub-types, with a vast range of characteristics. Som ...
OCT 14, 2020
Cancer
Using Plasma Scalpels with Chemotherapy Against Brain Cancer
OCT 14, 2020
Using Plasma Scalpels with Chemotherapy Against Brain Cancer
Cold atmospheric plasma is a relatively new technique that utilizes a tool that generates a sort of plasma scalpel, exce ...
Loading Comments...